免疫检查点抑制剂相关心肌炎诊疗进展
Advances in the management of immune checkpoint inhibitor-associated myocarditis
李泞甫 1李智可 1陈旭澜 2皈燕2
作者信息
- 1. 川北医学院附属医院肿瘤科(四川南充,637000);川北医学院临床医学系
- 2. 川北医学院附属医院肿瘤科(四川南充,637000)
- 折叠
摘要
免疫检查点抑制剂(immune checkpoint inhibitor,ICI)是肿瘤治疗的一大突破,在临床应用日益广泛.ICI相关心肌炎是ICI药物的罕见不良反应之一,病死率较高.尽管国内外均报道了该不良反应的治疗经验和指南,但部分医生在临床工作中仍存在认知不足、监管评估方案缺乏等问题.故本文对ICI相关心肌炎发病机制、诊断、治疗策略进行综述,以提高肿瘤科及心脏科医师的认识.
Abstract
Immune checkpoint inhibitors(ICI)are a major breakthrough in oncology treatment and are in-creasingly used in clinical practice.ICI-associated myocarditis is one of the rare adverse reactions to ICI drugs,with a high mortality rate.Guidelines for treating this adverse reaction have been written both domestically and in-ternationally at home and abroad.However,there is still a lack of awareness and reliable regulatory assessment protocols in clinical work.Therefore,this article reviews the pathogenesis,diagnosis,and treatment strategies of ICI-associated myocarditis in order to raise the awareness of oncologists and cardiologists.
关键词
心肌炎/免疫检查点抑制剂Key words
myocarditis/immune checkpoint inhibitor引用本文复制引用
基金项目
国家自然科学基金(20SXQT0329)
南充市市校合作科研专项(20SXQT0254)
南充市市校合作科研专项(20SXQT0071)
出版年
2024
NETL
NSTL
万方数据